Emerging guidelines for use of NSAID therapy to optimize cataract surgery patient care

References

• Flach AJ. Topical nonsteroidal antiinflammatory drugs in ophthalmology. Int Ophthalmol Clin 2002;42:1–11
   PubMedGoogle Scholar
• Heier JS, Topping TM, Baumann W, et al. Ketorolac versus prednisolone versus combination therapy in treatment of acute pseudophakic cystoid macular edema. Am Acad Ophthalmology 2000;107:2034–38
   PubMed Web of Science ®Google Scholar
• Flach AJ. Heier et al. Treatment of acute CME: Discussion: ketorolac vs. prednisolone vs. combination therapy in the treatment of acute CME. Ophthalmology 2000;107: 2039
   Google Scholar
• Solomon KD, Cheetham JK, DeGryse R, et al. Topical ketorolac tromethamine 0.5% ophthalmic solution in ocular inflammation after cataract surgery. Ophthalmology 2001;108:331–7
   Google Scholar
• Snyder RW. Preventing CME after cataract surgery. Ophthalmology management [online]. Available at: http://www.ophmanagement.com/article.aspx?article=&loc=archive\2003\april\allergan\0403allergan3.htm [accessed 04/28/05]
   Google Scholar
• Flach AJ, Jampol LM, Weinberg D, et al. Improvement in visual acuity in chronic aphakic and pseudophakic cystoid macular edema after treatment with topical 0.5% ketorolac tromethamine. Am J Ophthalmol 1991;112:514–9
   PubMed Web of Science ®Google Scholar
• Solomon LD. Efficacy of topical flurbiprofen and indomethacin in preventing pseudophakic cystoid macular edema [Flurbiprofen-CME Study Group I]. J Cataract Refract Surg 1995;21:73–81
   PubMed Web of Science ®Google Scholar
• Miyake K, Masuda K, Shirato S, et al. Comparison of diclofenac and fluorometholone in preventing cystoid macular edema after small incision cataract surgery: a multicentered prospective trial. Jpn J Ophthalmol 2000;44:58–67
   PubMed Web of Science ®Google Scholar
• Rho DS. Treatment of acute pseudophakic cystoid macular edema: diclofenac versus ketorolac. J Cataract Refract Surg 2003;29:2378–84
   PubMed Web of Science ®Google Scholar
• Weisz JM, Bressler NM, Bressler SB, Schachat AP. Ketorolac treatment of pseudophakic cystoid macular edema identified more than 24 months after cataract extraction. Ophthalmology 1999;106:1656–9
   PubMed Web of Science ®Google Scholar
• Flach AJ. Nonsteroidal anti-inflammatory drugs. In: Tasman W, editor. Duane’s foundations of clinical ophthalmology. Philadelphia: Lippincott; 1994. p. 1–32
   Google Scholar
• Flach AJ. Cyclo-oxygenase inhibitors in ophthalmology. Surv Ophthalmol 1992;36:259–84
   PubMed Web of Science ®Google Scholar
• Roberts CW, Brennan KM. A comparison of topical diclofenac with prednisolone for postcataract inflammation. Arch Ophthalmol 1995;113:725–7
   PubMed Web of Science ®Google Scholar
• Hsu JK, Johnston WT, Read RW, et al. Histopathology of corneal melting associated with diclofenac use after refractive surgery. J Cataract Refract Surg 2003;29:250–6
   PubMed Web of Science ®Google Scholar
• Snyder RW, Siekert RW, Schwiegerling J, et al. Acular as a single agent for use as an antimiotic and anti-inflammatory in cataract surgery. J Cataract Refract Surg 2000;26:1225–7
   PubMed Web of Science ®Google Scholar
• McColgin AZ, Raizman MB. Efficacy of topical Voltaren in reducing the incidence of postoperative cystoid macular edema. Invest Ophthalmol Vis Sci 1999;40(Suppl):289
   Google Scholar
• Guzek JP, Holm M, Cotter JB, et al. Risk factors for intraoperative complications in 1000 extracapsular cataract cases. Ophthalmology 1987;94:461–6
   PubMed Web of Science ®Google Scholar
• Stewart R, Grosserode R, Cheetham JK, et al. Efficacy and safety profile of ketorolac 0.5% ophthalmic solution in the prevention of surgically induced miosis during cataract surgery. Clin Ther 1999;21:723–32
   Google Scholar
• Roberts CW. Comparison of diclofenac sodium and flurbiprofen for inhibition of surgically induced miosis. J Cataract Refract Surg 1996;22(Suppl 1):780–7
   PubMedGoogle Scholar
• Samudre SS, Lattanzio Jr FA, Williams PB, Sheppard Jr JD. Comparison of topical steroids for acute anterior uveitis. J Ocul Pharmacol Ther 2004;20:533–47
   PubMed Web of Science ®Google Scholar
• Lu KL, Wee WR, Sakamoto T, McDonnell PJ. Comparison of in vitro antiproliferative effects of steroids and nonsteroidal anti-inflammatory drugs on human keratocytes. Cornea 1996;15:185–90
   PubMed Web of Science ®Google Scholar
• Nguyen KD, Lee DA. Effects of steroids and nonsteroidal antiinflammatory agents on human ocular fibroblast. Invest Ophthalmol Vis Sci 1992;33:2693–701
   PubMed Web of Science ®Google Scholar
• Nguyen KD, Lee DA. In vitro evaluation of antiproliferative potential of topical cyclo-oxygenase inhibitors in human Tenon’s fibroblasts. Exp Eye Res 1993;57:97–105
   PubMed Web of Science ®Google Scholar
• Nassaralla B, Szerenyi K, Wang XW, et al. Effect of diclofenac on corneal haze after photorefractive keratectomy in rabbits. Ophthalmology 1995;102:469–74
   PubMed Web of Science ®Google Scholar
• Simone JN, Pendelton RA, Jenkins JE. Comparison of the efficacy and safety of ketorolac tromethamine 0.5% and prednisolone acetate 1% after cataract surgery. J Cataract Refract Surg 1999;25: 599–704
   Google Scholar
• Flach AJ, Dolan BJ, Donahue ME, et al. Comparative effects of ketorolac 0.5% or diclofenac 0.1% ophthalmic solutions on inflammation after cataract surgery. Am J Ophthalmology 1998;105:1775–9
   Google Scholar
• El-Harazi SM, Ruiz RS, Feldman RM, et al. A randomized double-masked trial comparing ketorolac tromethamine 0.5%, diclofenac sodium 0.1%, and prednisolone acetate 1% in reducing post-phacoemulsification flare and cells. Ophthalmic Surg Lasers 1998;29: 439–544
   Google Scholar
• Roberts CW. Pretreatment with topical diclofenac sodium to decrease postoperative inflammation. Ophthalmology 1996;103:636–9
   PubMed Web of Science ®Google Scholar
• Nelson ML, Martidis A. Managing cystoid macular edema after cataract surgery. Curr Opin Ophthalmol 2003;14:39–43
   PubMedGoogle Scholar
• Heier, JS. Preventing post-cataract extraction CME: early identification of patients at risk and prophylactic treatment may avert vision loss. Ophthalmology Management October 2004;63–72
   Google Scholar
• Gills JP. Voltaren associated with medication keratitis [letter]. J Cataract Refract Surg 1994;20:110
   PubMed Web of Science ®Google Scholar
• Sher NA, Krueger RR, Teal R, Jans RG. Role of topical corticosteroids and nonsteroidal anti-inflammatory drugs in the etiology of stromal infiltrates after excimer photorefractive keratectomy. J Refract Corneal Surg 1994;10:587–8
   PubMedGoogle Scholar
• Probst LEV, Machat JJ. Corneal subepithelial infiltrates following photorefractive keratectomy [letter]. J Cataract Refract Surg 1996;22:281
   PubMed Web of Science ®Google Scholar
• Shimazaki J, Saito H, Yang HY, et al. Persistent epithelial defect following penetrating keratoplasty: an adverse effect of diclofenac eye drops. Cornea 1995;14:623–7
   PubMed Web of Science ®Google Scholar
• Congdon NG, Schein OD, von Kulajta P, et al. Corneal complications associated with topical ophthalmic use of nonsteroidal antiinflammatory drugs. J Cataract Refract Surg 2001;27:622–31
   PubMed Web of Science ®Google Scholar
• O’Brien TP, Li QJ, Sauerburger F, et al. The role of matrix metalloproteinases in ulcerative keratolysis associated with perioperative diclofenac use. Ophthalmology 2001;108:656–9
   Google Scholar
• Reviglio VE, Rana TS, Li QJ, et al. Effects of topical nonsteroidal antiinflammatory drugs on the expression of matrix metalloproteinases in the cornea. J Cataract Refract Surg 2003;29:989–97
   PubMed Web of Science ®Google Scholar
• Gaynes BI, Fiscella R. Topical nonsteroidal anti-inflammatory drugs for ophthalmic use: a safety review. Drug Saf 2002;25:233–50
   PubMed Web of Science ®Google Scholar
• Gamache DA, Graff G, Brady MT, et al. Nepafenac, a unique nonsteroidal pro-drug with potential utility in the treatment of trauma-induced ocular inflammation: I. Assessment of anti-inflammatory efficacy. Inflammation 2000;24:357–70
   Google Scholar
• Sher NA, Frantz JM, Talley A, et al. Topical diclofenac in the treatment of ocular pain after excimer photorefractive keratectomy. Refract Cornea Surg 1993;9:425–36
   PubMedGoogle Scholar
• McGee DH, Heaton JD, Gruebbel MM, et al. Ocular Effects of nepafenac ophthalmic suspension in New Zealand White rabbits undergoing partial corneal incisions. Paper presented at: Annual meeting of the Association for Research in Vision and Ophthalmology, May 03, 2005, Fort Lauderdale, FL
   Google Scholar
• Walker LM, Rice RL, Heaton JD, et al. Ocular effects of nepafenac ophthalmic suspension following three months of topical ocular administration to Cynomolgus monkeys. Paper presented at: Annual meeting of the Association for Research in Vision and Ophthalmology, May 03, 2005, Fort Lauderdale, FL
   Google Scholar
• Heaton J, Hiddemen JW, Hackett RB, et al. Ocular effects of nepafenac ophthalmic suspension following six months of topical ocular administration to pigmented rabbits. Paper presented at: Annual meeting of the Association for Research in Vision and Ophthalmology, May 03, 2005, Fort Lauderdale, FL
   Google Scholar
• Kern TS, Miller C, Du YP, et al. Topical administration of nepafenac inhibits the early stages of diabetic retinopathy. Paper presented at: Annual meeting of the Association for Research in Vision and Ophthalmology, May 03, 2005, Fort Lauderdale, FL
   Google Scholar
• Song Q, McCollum GW, Macrorie-Fairweather R, et al. Nepafenac metabolite, amfenac, inhibits VEGF induced phosphorylation of ERK in human retinal microvascular endothelial cells. Paper presented at: Annual meeting of the Association for Research in Vision and Ophthalmology, May 03, 2005, Fort Lauderdale, FL
   Google Scholar
• Ke TL, Graff G, Spellman JM, Yanni JM. Nepafenac, a unique nonsteroidal pro-drug with potential utility in the treatment of trauma-induced ocular inflammation: II. In vitro bioactivation and permeation of external ocular barriers. Inflammation 2000;24:371–84
   PubMed Web of Science ®Google Scholar
• Kapin MA, Yanni JM, Brady MT, et al. Inflammation-mediated retinal edema in the rabbit is inhibited by topical nepafenac. Inflammation 2003;27:281–91
   PubMed Web of Science ®Google Scholar
• Mishima H, Masuda K, Miyake K, et al. The putative role of prostaglandins in cystoid macular edema. Prog Clin Biol Res 1989;31:251–64
   Google Scholar
• Takahashi K, Saishin Y, Saishin Y, et al. Topical nepafenac inhibits ocular neovascularization. Invest Ophthalmol Vis Sci 2003;44:409–15
   PubMed Web of Science ®Google Scholar
• Lane SS, Modi SS, Holland EJ, et al. Nepafenac ophthalmic suspension 0.1% before and after surgery for postoperative anterior segment inflammation. Paper presented at: American Society of Cataract and Refractive Surgery, April 14, 2005, Washington, DC
   Google Scholar
• Donnenfeld ED, Holland EJ, Stewart R, Grillone LR. Topical xibrom 0.1% investigational NSAID to decrease inflammation after cataract surgery. Paper presented at: American Society of Cataract and Refractive Surgery; April 14, 2005, Washington, DC
   Google Scholar